GT Biopharma (GTBP) Expected to Announce Quarterly Earnings on Thursday

GT Biopharma (NASDAQ:GTBP) will likely be posting its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect GT Biopharma to post earnings of ($0.38) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 20, 2025 at 7:00 AM ET.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.13. On average, analysts expect GT Biopharma to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GT Biopharma Stock Up 6.2%

GTBP stock opened at $0.66 on Tuesday. The firm has a 50 day moving average of $0.73 and a 200 day moving average of $1.74. The stock has a market capitalization of $2.34 million, a PE ratio of -0.16 and a beta of 1.38. GT Biopharma has a 52 week low of $0.54 and a 52 week high of $4.10.

Wall Street Analyst Weigh In

GTBP has been the subject of a number of research analyst reports. Wall Street Zen cut shares of GT Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GT Biopharma has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.